The global plasma fractionation market is valued at $352.6 million in 2024 and is projected to reach $506.9 million by 2033, expanding at a 4.1% CAGR. Growth is underpinned by rising demand for immunoglobulin therapies in neurology and immunology, alongside albumin use in critical care. The Immunoglobulins Market alone represents over half of total revenue, while the Albumin Market remains essential for volume resuscitation. North America holds the largest share at 38%, driven by a mature plasma collection network and high per-capita immunoglobulin consumption.

Key macroeconomic forces include an aging population, increasing diagnosis of primary immunodeficiencies, and expanded access in Asia-Pacific. However, plasma collection constraints and regulatory hurdles temper growth. The Biologics Market, as the parent category, benefits from advances in purification and viral inactivation, reinforcing plasma-derived therapies as a critical component of modern medicine.

• Immunoglobulins command 52% revenue share, growing at 5.2% CAGR.
• North America leads with $134.0 million base valuation.
• Asia-Pacific is the fastest-growing region at 5.5% CAGR.
• Source Plasma Market supply remains tight, with collection shortfalls in Europe.
• Plasma Collection Market consolidation is raising per-liter costs by 3–5% annually.

The Immunoglobulins Market is the largest revenue-generating segment, with 52% share and 5.2% CAGR. Demand is driven by intravenous and subcutaneous immunoglobulin therapies for primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. The Immunology Therapeutics Market is expanding as new indications gain approval.

• Intravenous immunoglobulin (IVIG) accounts for 70% of immunoglobulin revenue, but subcutaneous formulations grow at 8% annually.
• Albumin Market is price-sensitive; 20% concentration products dominate critical care use.
• Coagulation Factor Concentrates Market faces pressure from recombinant factors, particularly for hemophilia A.

• Source plasma cost represents 40–50% of total production expenses, with Plasma Collection Market operators facing donor fee inflation.
• Chromatography resins and single-use systems add 10–15% to capital expenditure for new fractionation lines.
• The Hematology Treatment Market remains a stable but slower-growth outlet for factor concentrates.

Plasma fractionation growth is primarily fueled by 6–8% annual demand growth for immunoglobulin therapies in developed markets. The Immunology Therapeutics Market benefits from expanded labeling, while the Hematology Treatment Market relies on factor replacement. However, supply-side constraints are acute: global source plasma collection grew only 2–3% in 2024, below fractionation capacity growth. Regulatory frameworks such as FDA CBER and EMA requirements add 12–18 months to facility approvals.

• CSL Ltd.: Operates the largest plasma collection network and invests in immunoglobulin yield improvements.
• Takeda Pharmaceutical Co. Ltd.: Combines plasma-derived products with recombinant alternatives for hemophilia.
• Grifols SA: Controls source plasma supply through its own centers, reducing input cost volatility.
• Octapharma AG: Focuses on albumin and critical care products, with growing presence in Asia.
• Kedrion SpA: Specializes in regional fractionation and rare disease therapies in Europe.
• LFB SA: French fractionator with strong public health partnerships.
• Sanquin: Dutch blood bank and fractionator with a focus on self-sufficiency.

• January 2024: CSL announced a $200 million expansion of its fractionation facility in Switzerland, targeting a 15% increase in immunoglobulin output.
• March 2024: Grifols partnered with a European blood bank to secure additional source plasma, addressing a 10% supply gap.
• August 2024: Takeda launched a new subcutaneous immunoglobulin therapy, capturing 5% of the SCIG segment within two quarters.
• February 2025: Octapharma acquired three plasma collection centers in India, strengthening its Plasma Collection Market position.

North America remains the most mature market, with $134.0 million in 2024 and 4.0% CAGR. The United States drives demand through high immunoglobulin consumption and a dense Plasma Collection Market of over 800 centers. Europe follows at $102.3 million, with regulatory focus on plasma self-sufficiency and viral safety. Asia-Pacific is the fastest-growing corridor at 5.5% CAGR, led by China, India, and South Korea, where the Immunology Therapeutics Market is expanding rapidly. LAMEA shows 4.7% CAGR, supported by rising albumin use in critical care and improving healthcare infrastructure.

Chromatography-based purification is displacing traditional ethanol precipitation, improving immunoglobulin yield by 15–20%. The Plasma Chromatography Market is attracting investment from CSL, Grifols, and Takeda, with continuous manufacturing pilots reducing batch times by 30%. Nanofiltration and solvent-detergent methods enhance viral safety, while single-use systems lower cleaning validation costs.

• Continuous chromatography: Expected commercial adoption by 2027, offering 25% higher productivity.
• Recombinant substitutes: Gene therapy for hemophilia could reduce Coagulation Factor Concentrates Market demand by 5–10% by 2030.
• AI-driven donor screening: Improves Source Plasma Market efficiency by 8–12%.

The FDA CBER mandates nucleic acid testing for HIV, HBV, and HCV, adding 5–7% to collection costs. In Europe, the EMA requires a Plasma Master File, with audits every 3 years. China's NMPA restricts imported plasma products, boosting domestic players like GC Biopharma and SK Inc. India's CDSCO has streamlined approvals for immunoglobulin products, reducing timelines by 6 months. The Plasma Collection Market must comply with these evolving standards, with non-compliance risking facility shutdowns.

• 1. Plasma Fractionation Market Is Segmented By Product
  • 1.1. Immunoglobulins
  • 1.2. Albumin
  • 1.3. Coagulation factor concentrates
  • 1.4. Protease inhibitors
  • 1.5. Others
• 2. Application
  • 2.1. Immunology
  • 2.2. Neurology
  • 2.3. Hematology
  • 2.4. Critical care
  • 2.5. Others
• 3. Technology
  • 3.1. Chromatography
  • 3.2. Filtration
  • 3.3. Precipitation
  • 3.4. Rest of World (ROW

• 1. North America
  • 1.1. United States
  • 1.2. Canada
  • 1.3. Mexico
• 2. South America
  • 2.1. Brazil
  • 2.2. Argentina
  • 2.3. Rest of South America
• 3. Europe
  • 3.1. United Kingdom
  • 3.2. Germany
  • 3.3. France
  • 3.4. Italy
  • 3.5. Spain
  • 3.6. Russia
  • 3.7. Benelux
  • 3.8. Nordics
  • 3.9. Rest of Europe
• 4. Middle East & Africa
  • 4.1. Turkey
  • 4.2. Israel
  • 4.3. GCC
  • 4.4. North Africa
  • 4.5. South Africa
  • 4.6. Rest of Middle East & Africa
• 5. Asia Pacific
  • 5.1. China
  • 5.2. India
  • 5.3. Japan
  • 5.4. South Korea
  • 5.5. ASEAN
  • 5.6. Oceania
  • 5.7. Rest of Asia Pacific